Neither of the stocks I'm looking at today has performed well over the past 12 months, but that's not altogether surprising as both are in the ramp-up phase.
That's definitely a good thing, as it means there's plenty of upside to be had, provided the companies can derisk their projects and start generating real revenue.
These two companies are very different, with one being a mine project developer and the other having built an image analysis solution which helps diagnose heart problems.

Image source: Getty Images
New lithium hopeful emerges
The first company, Delta Lithium Ltd (ASX: DLI), is currently worth just $100.8 million, so it's firmly in small-cap territory.
On 13 November, Delta released a scoping study for its Mt Ida lithium project, which envisages a mine running for 11 years and generating $1.4 billion in free cash flow.
Given it's at the scoping study stage, there's plenty more work to be done, but on the positive side of the ledger, the project is fully permitted for both open pit and underground mining.
Managing Director James Croser said in a statement to the ASX on 17 November that the project also contained valuable tantalum and rubidium in the ore, with only minor changes to the processing method needed to separate them.
He said from now on:
Several value-adding activities will follow, including resource definition drilling, continued optimisation of the process flowsheet to reduce capital and operating costs and building upon work earlier this year on downstream recovery of rubidium and lithium carbonate from the lepidolite concentrate, with a firm view to maximising project potential for shareholders. Now that the scope of a potential lithium mine at Mt Ida has been outlined, Delta is well positioned to engage positively with industry partners on shared outcomes.
Bell Potter, in a research note published on 17 November, said it had reduced its price target for Delta from 41 cents to 30 cents in light of recent macroeconomic events.
This would still be a 122% return from the current level of 13.5 cents if achieved. The stock has fallen 40% over the past 12 months.
Heart imaging set to take off
Now turning to Artrya Ltd (ASX: AYA), which has experienced a 10.7% share price fall over the past year.
At the company's annual general meeting on 13 November, Chair Bernard Ridgeway said Artrya had shifted its focus to commercial execution about a year ago, and good progress was being made on that front.
The company had signed multi-year commercial contracts with five US health systems, "and we are in the early stages of a revenue-generating business''.
He added:
Artrya is targeting a market in the US that is large and growing every day. The U.S. market for CCTA scans is currently worth around US$4.4 billion a year and growing at a significant rate. The significant growth presents an immediate and genuine challenge for all health systems in the US. Volumes of scans are rising faster than the staffing and reporting capacity required to process them, and the legacy approach of manual scan reads is simply too slow to keep pace. Hospitals are currently carrying the cost and burden of an overwhelming number of patients with chest pain, and they need a simple and highly scalable technology solution.
Artrya's Salix Coronary Anatomy was built to address this problem, he said.
Morgans has rated the company a speculative buy, with a price target of $4.70, compared with $2.59 currently.
If realised, that would be an 81.5% return.
Morgans said it rates the management highly, "and the market is attractive, but it is early commercialisation and the pace of adoption is the swing factor''.